Capricor Therapeutics announced that the FDA extended the PDUFA target action date for its Duchenne muscular dystrophy therapy, Deramiocel, by three months to November 22, 2026. This extension is due to Capricor submitting additional Phase 3 data and analyses to support a refined proposed indication, which the FDA classified as a major amendment requiring more review time.
Capricor Therapeutics received a three-month extension for the FDA's review of its Biologics License Application (BLA) for Deramiocel, an investigational Duchenne muscular dystrophy treatment. This extension, from August 22 to November 22, 2026, is a result of Capricor submitting additional 24-month open-label extension data from its pivotal Phase 3 HOPE-3 study and robustness analyses, aiming for a refined indication focused on upper limb function. While not a rejection, the delay introduces uncertainty and pushes back the potential approval timeline, which could impact investor sentiment in the short term. However, the FDA's acceptance of the amendment and acknowledgment of unmet medical need in DMD, along with the company's proactive submission of more data, could be viewed positively in the long term as it aims to strengthen the BLA.